[08/02/19]
Posted on August 2, 2019 in Health Law News
Published by: Hall Render
This week, CMS released the 2020 Medicare Hospital Outpatient Prospective Payment System (“OPPS”) and Ambulatory Surgical Center Payment System Proposed Rule (“Proposed Rule”). Among a host of other items, CMS announced its intent to continue paying Average Sales Price (“ASP”) minus 22.5 percent for most drugs acquired under the 340B drug discount program (“340B... READ MORE
Tags: 340B, 340B Drug Discount Program, ASP, Average Sales Price, OPPS, Outpatient Prospective Payment System, proposed rule
[05/08/19]
Posted on May 8, 2019 in Health Law News
Published by: Hall Render
On May 6, 2019, the United States District Court in Washington, D.C. issued its opinion on the appropriate remedy to address the invalidated payment cuts set forth in the 2018 and 2019 Outpatient Prospective Payment System final rules (“2018 and 2019 OPPS Rules”) for drugs purchased under the 340B drug discount program (“340B Program”).... READ MORE
Tags: 340 Drug Discount Program, 340B, AHA v. Azar, Centers for Medicare & Medicaid Services, cms, Medicare reimbursement, Outpatient Prospective Payment System, Part B, Payment Reduction
[04/19/19]
Posted on April 19, 2019 in Health Law News
Published by: Hall Render
We continue to receive questions regarding the future of the 340B drug discount program (“340B Program”) now that its mid-term longevity is no longer in doubt. These include whether Congress will continue to focus on limiting the 340B Program’s scope as well as what effect, if any, broader efforts to reduce drug costs might... READ MORE
Tags: 340B, 340B drugs, 340B Program, Ceiling Price, Drug Prices, HRSA, Medicare Part B, Office of Pharmacy Affairs, OPA, pharmacy
[04/05/19]
Posted on April 5, 2019 in Health Law News
Published by: Hall Render
It’s no April Fools’ joke. On April 1, 2019, the Health Resources & Services Administration Office of Pharmacy Affairs (“HRSA”) unveiled a long-awaited website that gives providers participating in the 340B drug pricing program (“340B Program”) direct access to information about the maximum amounts that pharmaceutical companies may charge for certain drugs. This moves... READ MORE
Tags: 340B, ACA, Affordable Care Act, ASP, Ceiling Price, cms, Health Resources & Services Administration Office of Pharmacy Affairs, HRSA, Office of Pharmacy Affairs Information System, OPA, OPAIS, OPPS, Outpatient Prospective Payment System, pharmacy
[03/29/19]
Posted on March 29, 2019 in Federal Advocacy
Published by: Hall Render
Conversation Shifts Back to Health Care in Washington Health care became a major discussion point for lawmakers after this week started with the Trump administration’s declaration that it supports a federal judge’s ruling that the entire Affordable Care Act (“ACA”) should be thrown out. This signals a shift in the Justice Department’s prior position... READ MORE
Tags: 340B, ACA, Affordable Care Act, House Energy and Commerce Health Subcommittee, House Energy and Commerce Oversight and Investigations Subcommittee, Medicare, This Week in Washington
[01/11/19]
Posted on January 11, 2019 in Health Law News
Published by: Hall Render
On December 27, 2018, a federal judge ruled in favor of hospital associations and hospitals challenging the reduction in reimbursement for drugs purchased at a discount under the 340B Program established in the 2018 Outpatient Prospective Payment System final rule (“2018 OPPS Rule”). Judge Rudolph Contreras of the United States District Court in Washington,... READ MORE
Tags: 340B, 340B Payment Cuts, 340B Program, cms, hhs, OPPS, Outpatient Prospective Payment System
[11/30/18]
Posted on November 30, 2018 in Federal Advocacy
Published by: Hall Render
Congress Unlikely to Make Progress on Health Care Bills Before Year-End As government funding battles overtake Capitol Hill, it appears Congress will not use the lame duck to resolve outstanding health care issues. While the desire to steer clear of health care fights is something different from prior years, outgoing House Ways and Means... READ MORE
Tags: 340B, 340B Penalties, Affordable Care Act, EHRs, electronic health records, Lame Duck Session, This Week in Washington
[11/16/18]
Posted on November 16, 2018 in Federal Advocacy
Published by: Hall Render
Democrats Set to Control Key Health Committees in Next Session of Congress The Democratic takeover of the House of Representatives following the recent midterm elections will significantly change the political landscape for health care issues when lawmakers return for the 116th Session of Congress next year. Overall, the election results will mean divided government... READ MORE
Tags: 340B, Affordable Care Act, IMD exclusion, Mental Health Treatment, Opioid Legislation, pharma, pre-existing conditions, This Week in Washington
[09/21/18]
Posted on September 21, 2018 in Federal Advocacy
Published by: Hall Render
Hospitals Release Voluntary 340B Principles as Alternative to Legislation The battle over 340B continued this week as hospital groups announced a new voluntary 340B reporting program as an alternative to congressional legislation that would further regulate the program. Under the American Hospital Association-led initiative, hospitals would commit to publicly disclosing their 340B savings annually.... READ MORE
Tags: 340B, Conditions of Participation, Medicare, Reducing Administrative Costs and Burdens in Health Care Act, This Week in Washington
[09/19/18]
Posted on September 19, 2018 in Health Law News
Published by: Hall Render
On August 7, 2018, the Centers for Medicare & Medicaid Services (“CMS”) issued a Memorandum (“Memorandum”) announcing a policy change to allow Medicare Advantage (“MA”) plans to implement step therapy programs for physician-administered and other Part B drugs. Step therapy is a type of prior authorization for drugs in which a health plan requires... READ MORE
Tags: 340B, Centers for Medicare and Medicaid Services, cms, MA plans, MA-PD plans, Medicare Advantage, Medicare Part B, pharmacy benefit managers, Step Therapy